Trial Profile
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- Sponsors Endo International
- 13 Mar 2023 According to an Endo International media release, Joseph M. Caporusso is a lead clinical investigator for this study.
- 13 Mar 2023 Primary endpoint (Mean Change between EN3835 and placebo in the Foot Function Index (FFI) pain subscale) has not been met, according to an Endo International media release.
- 13 Mar 2023 Results published in an Endo International Media Release.